- Home
- PALI vs CLLS Comparison
PALI vs CLLS Comparison
Compare PALI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PALI | CLLS |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.7M | 394.4M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PALI | CLLS |
|---|---|---|
| Price | $1.91 | $2.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $11.29 | $8.33 |
| AVG Volume (30 Days) | ★ 2.8M | 12.5K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.06 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $260,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1500.39 | N/A |
| 52 Week Low | $0.55 | $2.48 |
| 52 Week High | $2.86 | $5.48 |
Technical Indicators
Market Signals| Indicator | PALI | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 41.79 |
| Support Level | $1.57 | $2.65 |
| Resistance Level | $2.13 | $2.98 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 15.28 | 41.03 |
Price Performance
Historical ComparisonAbout PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.